ETM
BRLI

Euclidean Technologies Management’s BIO-REFERENCE LABS INC-NEW- BRLI Stock Holding History

Euclidean Technologies Management’s Portfolio BRLI Stock Details BRLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-10,000
Closed -$321K – 54
2014
Q4 		$321K Hold
10,000
– – 0.3% 40
2014
Q3 		$281K Hold
10,000
– – 0.26% 38
2014
Q2 		$302K Hold
10,000
– – 0.27% 40
2014
Q1 		$277K Buy
+10,000
New +$262K 0.24% 37

Other funds holding BRLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Euclidean Technologies Management's BRLI Position: Q1 2015 in Review

Euclidean Technologies Management sold out of BIO-REFERENCE LABS INC-NEW- (BRLI) in Q1 2015, closing a stake of 10,000 shares — an estimated $321K sold.

Euclidean Technologies Management first reported a position in BRLI in Q1 2014 and held it in 4 quarters. The position peaked at $321K in Q4 2014. 168 funds tracked by Wall St. Rank hold BRLI as of Q1 2015.

  • Euclidean Technologies Management reported no remaining BIO-REFERENCE LABS INC-NEW- position as of Q1 2015 after selling out during the quarter.
  • Euclidean Technologies Management sold 10,000 BIO-REFERENCE LABS INC-NEW- shares in Q1 2015, an estimated $321K.
  • Euclidean Technologies Management first reported a position in BIO-REFERENCE LABS INC-NEW- in Q1 2014 and held it in 4 quarters.
  • Euclidean Technologies Management's BIO-REFERENCE LABS INC-NEW- position peaked at $321K in Q4 2014.
  • 168 funds tracked by Wall St. Rank held BIO-REFERENCE LABS INC-NEW- as of Q1 2015.

Based on Euclidean Technologies Management's 13F filing for Q1 2015, filed 15 May 2015.